Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the company's announcement of interim results from its Phase 1b multiple-ascending ...

Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price movement reflects a continued downtrend for the biopharmaceutical company, which ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Regulus Resources (CVE:REG) stock is up 137% in the last year, providing strong gains for shareholders. But the ...

I pick out North America’s celestial highlights for the week ahead (which also apply to mid-northern latitudes in the northern hemisphere).

Tonight's full Snow Moon will have a royal companion as it rises alongside Regulus, a star nicknamed "Heart of the Lion", in ...

This month's full "Snow Moon" will be joined by a bright star in the night sky, called Regulus, nicknamed "Heart of the Lion" ...

SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...

The Northern Hemisphere will have a beautiful event on Wednesday, February 12, when the second full moon of the year occurs, which is called the "Snow Moon". This spectacle will be ...

Therapeutics announced positive clinical and regulatory updates from its ADPKD program. The update includes positive topline ...